SEC Filing Summary
Entity and period: The supplied filing is PlasmaTech Biopharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 31, 2015. It is not an Abeona Therapeutics filing, and it reports an annual period rather than standalone 2014 Q4 results.
Business context and reporting period
PlasmaTech was an emerging biopharmaceutical company developing nanopolymer-based products and, following a 2014 license, a salt diafiltration (SDF) process for plasma-derived biologics. Its marketed product was MuGard, licensed across several territories; ProctiGard received FDA 510(k) clearance in July 2014. The company was seeking commercial partners and developing additional candidates, including A1PI and IVIG products based on SDF technology.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Total revenue | $925,000 | $2,042,000 |
| Operating expenses | $4,056,000 | $5,846,000 |
| Loss from operations | $3,131,000 | $3,804,000 |
| Net income (loss) | $(26,778,000) | $4,449,000 |
| Net income (loss) allocable to common stockholders | $(29,653,000) | $1,551,000 |
| Operating cash flow | $1,611,000 | $1,000 |
| Cash and cash equivalents at year-end | $11,520,000 | $424,000 |
| Working capital | $8,657,000 | $(8,386,000) |
- Revenue fell about 55%. No MuGard product sales were recorded in 2014 after the U.S. license to AMAG; licensing revenue was $598,000 and royalties were $327,000.
- Operating expenses declined about 31%, including lower R&D spending ($333,000 versus $884,000) and lower SG&A ($3,712,000 versus $4,834,000).
- The reported 2014 loss included a $23.11 million noncash loss from revaluing the Series A preferred-stock derivative liability. The preferred stock was converted to common stock on December 24, 2014; the derivative liability was eliminated. The 2013 result included an $8.01 million gain from this valuation item.
- Operating cash flow was positive despite the net loss, primarily because the cash-flow reconciliation added back the $23.11 million derivative loss and included other noncash and working-capital items. The filing does not provide a conventional EBITDA or cash-burn figure.
- Year-end current liabilities were $2.898 million, including $400,000 of short-term notes; the notes were repaid January 5, 2015. A separate $4 million payment obligation to the SDF licensor is due in 2017, payable in cash or shares under the agreement.
- Cash rose mainly following a December public offering that generated $12.307 million net proceeds. The offering issued 3.5 million shares and warrants for 3.5 million shares at a $5 exercise price. Preferred-stock balances and accrued amounts were also converted into common shares.
Changes, outlook, risks, and unusual items
- Management said available resources, royalties, and expected license receipts were expected to fund the current operating level into the second quarter of 2016, while also warning that financing might be needed within 12 months depending on spending and obligations. The company expected continued losses and no significant near-term revenue.
- The company licensed worldwide SDF technology for plasma biologics. Consideration included a $1 million cash license fee, a $4 million payment in 2017 (cash or shares), an FDA-approval milestone payable in shares, and sales-based royalties. Potential higher yields and expanded product opportunities are management expectations, not established commercial results.
- MuGard licensing expanded during 2014: Hanmi for South Korea and Norgine for Europe, Australia, and New Zealand. Norgine anticipated a European launch in 2015 and the agreement provided for up to $10 million in milestones plus royalties. Actual launch, sales, and milestone receipts were uncertain.
- The company reported a material weakness in internal control over financial reporting related to review and monitoring of accounting work and inadequate segregation of duties. Management said it hired additional personnel and implemented review procedures, but concluded controls were ineffective at December 31, 2014. The auditor did not attest to internal-control effectiveness.
- A purported class action concerning historical Genaera asset transactions was remanded for further proceedings; the company said it would contest the claims. The filing does not provide a clear estimate of potential financial exposure.
- Other significant risks include ongoing operating losses, reliance on licensees and external manufacturers, need for additional capital, clinical and regulatory uncertainty, competition, intellectual-property challenges, and concentrated ownership. The filing disclosed approximately $200.7 million of net operating loss carryforwards, potentially subject to ownership-change limitations.
Important facts for investors to verify
- Confirm the issuer and reporting period: this is PlasmaTech’s 2014 Form 10-K, not an Abeona Therapeutics filing or a standalone Q4 report.
- Review the audited statements and notes for the preferred-stock derivative valuation, conversion accounting, and noncash components of reported earnings and operating cash flow.
- Verify post-year-end cash needs, the stated runway, and whether licensing royalties or milestones and any additional financing support the outlook.
- Track SDF technology validation, regulatory progress, the 2017 $4 million obligation, and any potential share issuance or royalties under the license.
- Assess progress in remediating the disclosed material weakness and monitor the status and potential exposure of the pending litigation.